Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danaparoid vs Argatroban in Acute HIT (HITSOVA)
NCT03809481Phase 3Terminated
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Biologic
- Countries
- 9
01
Overview
A Phase 3 trial of danaparoid sodium in heparin-induced thrombocytopenia (HIT). Started May 2019; status: terminated.
02
Drugs
danaparoid sodium
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT03809481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809481.